1. Home
  2. APLM vs MNDR Comparison

APLM vs MNDR Comparison

Compare APLM & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • MNDR
  • Stock Information
  • Founded
  • APLM 2016
  • MNDR 2016
  • Country
  • APLM United States
  • MNDR Singapore
  • Employees
  • APLM N/A
  • MNDR N/A
  • Industry
  • APLM Blank Checks
  • MNDR
  • Sector
  • APLM Finance
  • MNDR
  • Exchange
  • APLM Nasdaq
  • MNDR Nasdaq
  • Market Cap
  • APLM 6.1M
  • MNDR 6.8M
  • IPO Year
  • APLM N/A
  • MNDR 2024
  • Fundamental
  • Price
  • APLM $5.48
  • MNDR $0.96
  • Analyst Decision
  • APLM
  • MNDR
  • Analyst Count
  • APLM 0
  • MNDR 0
  • Target Price
  • APLM N/A
  • MNDR N/A
  • AVG Volume (30 Days)
  • APLM 33.5K
  • MNDR 397.2K
  • Earning Date
  • APLM 09-16-2025
  • MNDR 10-28-2025
  • Dividend Yield
  • APLM N/A
  • MNDR N/A
  • EPS Growth
  • APLM N/A
  • MNDR N/A
  • EPS
  • APLM N/A
  • MNDR N/A
  • Revenue
  • APLM $198,000.00
  • MNDR $11,600,567.00
  • Revenue This Year
  • APLM $415.15
  • MNDR $188,831.77
  • Revenue Next Year
  • APLM N/A
  • MNDR $76.44
  • P/E Ratio
  • APLM N/A
  • MNDR N/A
  • Revenue Growth
  • APLM N/A
  • MNDR 0.61
  • 52 Week Low
  • APLM $3.66
  • MNDR $0.84
  • 52 Week High
  • APLM $35.98
  • MNDR $8.00
  • Technical
  • Relative Strength Index (RSI)
  • APLM 49.97
  • MNDR 43.33
  • Support Level
  • APLM $3.66
  • MNDR $0.93
  • Resistance Level
  • APLM $6.37
  • MNDR $1.08
  • Average True Range (ATR)
  • APLM 0.54
  • MNDR 0.06
  • MACD
  • APLM -0.10
  • MNDR -0.01
  • Stochastic Oscillator
  • APLM 67.17
  • MNDR 14.89

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About MNDR Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.

Share on Social Networks: